Stockreport

HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC [Yahoo! Finance]

HUTCHMED (China) Limited - American Depositary Shares  (HCM) 
NASDAQ:AMEX Investor Relations: chi-med.com/investors/information-for-shareholders
PDF — If approved, would confirm 2021 conditional approval and expand indication to more patients — HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., March 27, 2024 ( [Read more]